title: Preventing cisplatin induced ototoxicity by N-acetylcysteine and salicylate.
abstract: OBJECTIVE
  In this study we investigated if CP induced ototoxicity could be prevented or reduced by the use of salicylate and N-acetylcysteine.
  
  
  METHODS
  Fifty-four patients (28 females, 26 males; mean age 37+/-9.5 years; range 29 to 71 years) who had cisplatin chemotherapy due to solid organ tumors were enrolled in the study. The patients were randomized into three groups, with 18 patients in each group. The first group (control group) received cisplatin, second group received N-acetylcysteine (NAC; 600 mg/day) with cisplatin and the third group received salicylate (300 mg/day) with cisplatin. All patients evaluated audiologically including high frequency audiometry and auditory brainstem response.
  
  
  RESULTS
  The cisplatin-induced ototoxic damage could be reduced in 10,000 and 12,000 Hz frequencies when N-acetylcysteine was added to the cisplatin therapy protocol. There was no decrease in the hearing loss levels of the patients who were receiving cisplatin with salicylate.
  
  
  CONCLUSIONS
  According to auditory brainstem response testing results, there was no difference detected between N-acetylcysteine or salicylate for the amelioration of cisplatin induced ototoxicity.
authors.affiliation: Department of Otolaryngology, Medicine Faculty of Dicle University, Diyarbakir, Turkey.
authors.forename: Müzeyyen
authors.initials: M
authors.lastname: Yıldırım
authors.forename: Hasan Mete
authors.initials: HM
authors.lastname: Inançlı
authors.forename: Baver
authors.initials: B
authors.lastname: Samancı
authors.forename: Mehmet Faruk
authors.initials: MF
authors.lastname: Oktay
authors.forename: Murat
authors.initials: M
authors.lastname: Enöz
authors.forename: Ismail
authors.initials: I
authors.lastname: Topçu
mesh_terms: D000111:Acetylcysteine / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D001298:Audiology; D001301:Audiometry, Pure-Tone; D001309:Auditory Threshold / Q000187:drug effects; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use / Q000633:toxicity*; D016057:Evoked Potentials, Auditory, Brain Stem / Q000187:drug effects; D005260:Female; D034381:Hearing Loss / Q000139:chemically induced / Q000517:prevention & control; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy; D012459:Salicylates / Q000627:therapeutic use*
chemical_list: D012459:Salicylates; D002945:Cisplatin; D000111:Acetylcysteine